XML 62 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2012
Cash flows from operating activities:      
Net income $ 9,000,000 $ 8,450,000 $ 7,919,000
Depreciation and amortization 3,844,000 3,432,000 2,215,000
Gain on dispositions, net (420,000)    
Deferred income taxes (43,000) (291,000) (258,000)
Stock-based compensation 840,000 1,112,000 464,000
Impairment of intangible asset     350,000
Contingent consideration (1,020,000)    
Change in assets and liabilities, net of effects of acquisitions and dispositions      
Accounts receivable, net 697,000 (1,510,000) 493,000
Inventories, net (1,300,000) (228,000) 1,276,000
Prepaid expenses and other (1,479,000) (189,000) 38,000
Accounts payable 754,000 437,000 (150,000)
Accrued liabilities and taxes payable 1,192,000 189,000 142,000
Unearned revenues 308,000    
Net cash provided by operating activities 12,373,000 11,402,000 12,489,000
Cash flows from investing activities:      
Acquisitions (22,758,000) (16,660,000) (737,000) [1]
Proceeds from disposition 661,000    
Purchases of property, plant and equipment (1,041,000) (908,000) (683,000)
Net cash used in investing activities (23,138,000) (17,568,000) (1,420,000)
Cash flow from financing activities:      
Proceeds from the issuance of debt 21,000,000 11,000,000  
Payments on debt (8,500,000) (7,000,000) (6,500,000)
Dividends (1,989,000) (1,815,000) (1,645,000)
Proceeds from the exercise of stock options 1,845,000 898,000 1,318,000
Purchase and retirement of common stock (22,000) (102,000) (597,000)
Net cash provided by (used in) financing activities 12,334,000 2,981,000 (7,424,000)
Net increase (decrease) in cash and cash equivalents 1,569,000 (3,185,000) 3,645,000
Cash and cash equivalents at beginning of year 4,006,000 7,191,000 3,546,000
Cash and cash equivalents at end of year 5,575,000 4,006,000 7,191,000
Cash paid during the year for:      
Income taxes 4,714,000 4,778,000 4,457,000
Cash paid for interest 133,000 116,000 176,000
Supplemental non-cash activity:      
Employee loans issued for exercise of stock options   203,000 396,000
Repayment of employee loans for stock options 92,000 450,000 437,000
Contingent consideration as part of an acquisition $ 500,000 $ 2,140,000  
[1] In December 2011, we settled the $600 holdback amount from our acquisition of the assets of Apex Laboratories, Inc. by paying $562 and returning $38 of accounts receivable.